Ublituximab Bests Teriflunomide for MS in Two Phase 3 Trials
Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.
Source: medscape.com
Page 4 - S Relapse News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from S Relapse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In S Relapse Today - Breaking & Trending Today
Novel Drug for Relapsing-Remitting MS: New Phase 2 Data
The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.
Source: medscape.com
No Clear Answers From MS Drug Discontinuation Trial
The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.
Source: medscape.com
Novel Drug Tied to Slowed Disease Progression in Relapsing MS
The novel anti-CD20 monoclonal antibody ublituximab showed greater improvement vs terifulnomide in stabilizing disease progression in relapsing multiple sclerosis in two phase 3 trials.
Source: medscape.com
Novel Drug Safe, Effective in Relapsing MS: 2-Year Data
The investigational evobrutinib, an Bruton's tyrosine kinase inhibitor, showed favorable safety and efficacy in the longest trial to date of a drug in this class in patients with multiple sclerosis.
Source: medscape.com